Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Core Insights - Merus N.V. has entered into an exclusive licensing agreement with Partner Therapeutics, Inc. (PTx) for the commercialization of zenocutuzumab (Zeno) in the U.S. for NRG1 fusion-positive cancer [1][2] - Zeno is positioned to be the first targeted therapy for patients with NRG1+ non-small cell lung cancer (NSCLC) and pancreatic cancer, potentially offering significant improvements over existing treatments [2][3] - The U.S. Food and Drug Administration is currently reviewing a Biologics License Application for Zeno aimed at previously treated NRG1+ NSCLC and pancreatic cancer patients [3] Company Overview - Merus N.V. is a clinical-stage oncology company focused on developing innovative multispecific antibodies, known as Biclonics® and Triclonics® [1][7] - Partner Therapeutics, Inc. is a fully-integrated biotechnology company specializing in hematology and oncology, aiming to enhance health outcomes through therapeutic development [6] Product Details - Zeno utilizes the Merus Dock & Block® mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway, showing promise in preclinical studies for effectively targeting NRG1+ cancers [4] - The mechanism of Zeno involves blocking HER2 and preventing HER3 from interacting with its ligand, which is crucial for tumor cell proliferation and survival [4] Market Potential - NRG1 fusions are rare but significant genomic events in certain cancers, including NSCLC and pancreatic ductal adenocarcinoma (PDAC), indicating a specific market need for targeted therapies like Zeno [5] - The agreement allows Merus to receive an upfront payment, milestone payments, and royalties based on Zeno's annual net sales in the U.S. [2]